We used three independent cohorts of GBM patients to evaluate the correlation of TSPO genetic variant with the overall survival (OS) and progression-free survival (PFS) time, incorporating biological sex and treatment-specific analysis. The gene discussed is TSPO; the disease is glioblastoma.